Hip Fracture Risk in Patients With a Diagnosis of Pernicious Anemia
Background & Aims
Pernicious anemia (PA) is characterized by vitamin B-12 deficiency and achlorhydria, both of which have a detrimental effect on bone strength. The principle aim of this study was to determine the risk of hip fracture in patients with PA.
Methods
This is a retrospective cohort study using the General Practice Research Database (GPRD) from the United Kingdom. GPRD data from May 1987 until April 2002 were utilized to identify patients between 40 and 90 years of age at the time of GPRD enrollment. The exposed group contained patients with a diagnosis of PA being treated with vitamin B-12 therapy. We matched each patient having a diagnosis of PA with 4 randomly selected non-PA patients with respect to age (±1 year) and sex. Cox regression analysis was used to determine the hazard ratio (HR) for hip fracture associated with PA.
Results
Nine thousand five hundred six patients with a diagnosis of PA receiving vitamin B-12 injection therapy were identified and compared to 38,024 controls. Patients with PA had a greater risk of hip fracture than the controls (HR = 1.74; 95% CI: 1.45−2.08). The increase in hip fracture risk was even more pronounced among those patients newly diagnosed with PA during GPRD follow-up (HR = 2.63; 95% CI: 2.03−3.41).
Conclusions
Patients with a diagnosis of PA have an elevated risk of hip fracture. The increased hip fracture risk was persistent even years after vitamin B-12 therapy. Chronic achlorhydria could be the mechanism contributing to the persistently elevated hip fracture risk.
Keywords: Pernicious anemia, Vitamin B-12, Osteoporosis, Hip fracture
Abbreviations used in this paper: BMI, body mass index, CI, confidence interval, GPRD, General Practice Research Database, HR, hazard ratio, PA, pernicious anemia, PPI, proton pump inhibitors.
To access this article, please choose from the options below
Conflicts of interest The authors disclose the following: Dr Metz reports serving as a consultant and receiving honoraria and/or grant support from AstraZeneca, TAP Pharmaceutical Products, Altana, Wyeth-Ayerst Laboratories, Santarus, and Eisai. Dr Yang reports having served as a consultant for AstraZeneca and received grant support from AstraZeneca and GlaxoSmithKline. The remaining auhors disclose no conflicts.
Funding Dr Merriman was supported by a National Institutes of Health educational training grant during his gastroenterology and epidemiologic training at the University of Pennsylvania. Dr Yang was supported by a National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases Mentored Career Development Award (K08 DK062978), which also funded the access to the data in the General Practice Research Database. This study was supported by an academic development fund from the University of Pennsylvania to Dr Yang. The funding sponsors played no role in the study design in the collection, analysis, and interpretation of data.
PII: S0016-5085(09)02145-3
doi:10.1053/j.gastro.2009.12.007
© 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

